WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 317370
CAS#: 28860-95-9 (anhydrous)
Description: Carbidopa is a drug given to people with Parkinson's disease in order to inhibit peripheral metabolism of levodopa. This property is significant in that it allows a greater proportion of peripheral levodopa to cross the blood–brain barrier for central nervous system effect.
MedKoo Cat#: 317370
Name: Carbidopa (free base)
CAS#: 28860-95-9 (anhydrous)
Chemical Formula: C10H14N2O4
Exact Mass: 226.09536
Molecular Weight: 226.23
Elemental Analysis: C, 53.09; H, 6.24; N, 12.38; O, 28.29
Synonym: MK485, MK 485, MK-485, Carbidopa, Lodosyn
IUPAC/Chemical Name: (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid
InChi Key: TZFNLOMSOLWIDK-JTQLQIEISA-N
InChi Code: InChI=1S/C10H14N2O4/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6/h2-4,12-14H,5,11H2,1H3,(H,15,16)/t10-/m0/s1
SMILES Code: O=C(O)[C@@](C)(NN)CC1=CC=C(O)C(O)=C1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 226.23 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Calandra-Buonaura G, Doria A, Lopane G, Guaraldi P, Capellari S, Martinelli P,
Cortelli P, Contin M. Pharmacodynamics of a low subacute levodopa dose helps
distinguish between multiple system atrophy with predominant Parkinsonism and
Parkinson's disease. J Neurol. 2015 Nov 14. [Epub ahead of print] PubMed PMID:
2: Zhang D, McGregor M, Bordia T, Perez XA, McIntosh JM, Decker MW, Quik M. α7
nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe
nigrostriatal damage. Mov Disord. 2015 Nov 17. doi: 10.1002/mds.26453. [Epub
ahead of print] Review. PubMed PMID: 26573698.
3: Battista JP, Greene PE. Improvement of Primary Writing Tremor in Parkinson's
Disease with Carbidopa/Levodopa. Tremor Other Hyperkinet Mov (N Y). 2015 Oct
22;5:345. doi: 10.7916/D8WQ035T. eCollection 2015. PubMed PMID: 26566458; PubMed
Central PMCID: PMC4636028.